| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H10F2N2O5 |
| Molecular Weight | 264.1829 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(F)(F)[C@@H]1O
InChI
InChIKey=FIRDBEQIJQERSE-QPPQHZFASA-N
InChI=1S/C9H10F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h1-2,4,6-7,14,16H,3H2,(H,12,15,17)/t4-,6-,7-/m1/s1
| Molecular Formula | C9H10F2N2O5 |
| Molecular Weight | 264.1829 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. | 2001 Nov |
|
| Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. | 2002 Jun |
|
| In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU). | 2003 |
|
| Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. | 2003 Feb 15 |
|
| Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. | 2003 Mar |
|
| An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography. | 2003 Oct |
|
| Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry. | 2004 |
|
| Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. | 2004 Dec 10 |
|
| Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. | 2004 Mar |
|
| Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. | 2005 |
|
| Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. | 2005 May-Jun |
|
| Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. | 2006 |
|
| Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. | 2006 Dec |
|
| Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. | 2006 Nov-Dec |
|
| Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. | 2007 |
|
| Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. | 2007 Jan 1 |
|
| Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. | 2007 Mar-Apr |
|
| Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. | 2008 Mar |
|
| Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. | 2010 Aug |
|
| Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. | 2010 Jun |
|
| Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. | 2010 Sep |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9871558 | PRIMARY | |||
|
114248-23-6 | PRIMARY | |||
|
DTXSID50891460 | PRIMARY | |||
|
Y30D8SIL1I | PRIMARY |
